www.fdanews.com/articles/74969-santhera-and-takeda-establish-collaboration-to-develop-and-market-idebenone-snt-mc17
SANTHERA AND TAKEDA ESTABLISH COLLABORATION TO DEVELOP AND MARKET IDEBENONE (SNT-MC17)
August 3, 2005
Santhera Pharmaceuticals AG ("Santhera") of Switzerland and Takeda Pharmaceutical Company Limited ("Takeda") of Japan announced today that they will collaborate to develop and commercialize Idebenone (SNT-MC17), a small molecule drug for the treatment of Friedreich's Ataxia ("FRDA"). The clinical development for FRDA is about to enter a Phase III clinical study in Europe and will enter a Phase III study in the US shortly thereafter. The product has orphan drug designation in the US and Europe.
PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=261569)